Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
New Data Show Longer Tysabri Dosing Interval in MS Is Feasible
SIRT1 Deficiency in Microglia Contributes to Cognitive Decline in Aging and Neurodegeneration via Epigenetic Regulation of IL-1β.
Consensus Recommendations for the Diagnosis and Treatment of Multiple Sclerosis The Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS).
Mirna-Mediated Macrophage Polarization and its Potential Role in the Regulation of Inflammatory Response.
Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells.
Demyelination and other neurological adverse events after anti-TNF therapy.
[Retinal vasculitis as manifestation of multiple sclerosis.]
A validated regulatory network for Th17 cell specification.
How type I interferons shape myeloid cell function in CNS autoimmunity.
IL-17: A new actor in IFN-driven systemic autoimmune diseases.
We are about to cure multiple sclerosis in the next 10 years, even though we do not know its cause: Yes.
Vitamin d and multiple sclerosis.
Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis.
Drug therapy for multiple sclerosis.
IL-17 induces MIP-1α expression in primary mouse astrocytes via TRPC channel.
Glial Cell Development and Function in Zebrafish.
Medical marijuana in neurology.
IFNβ secreted by microglia mediates clearance of myelin debris in CNS autoimmunity.
Cognitive reserve in multiple sclerosis: Protective effects of education.
Does jcv antibody positivity encourage cessation of natalizumab therapy in multiple sclerosis?
Recurrent Varicella following Steroids and Fingolimod in a Multiple Sclerosis Patient.
Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US.
Multimodal noninvasive and invasive imaging of extracranial venous abnormalities indicative of CCSVI: results of the PREMiSe pilot study.
Characterization of the interaction between astrocytes and encephalitogenic lymphocytes during the development of experimental autoimmune encephalitomyelitis (EAE) in mice.
Suppression of the lipid peroxidation process in the CNS reduces neurological expression of experimentally induced autoimmune encephalomyelitis.
Pages
« first
‹ previous
…
304
305
306
307
308
309
310
311
312
…
next ›
last »